Björn has over 25 years’ experience in drug discovery, preclinical development, and CMC development of Biotherapeutics. He obtained experience in big- and mid-sized Pharma companies as well as in small biotech. He was involved in the development of several marketed products including Bavencio and Rekovelle. He was involved in research and development of several biotherapeutics which are currently in clinical development. His expertise covers all kinds or types of modalities including monoclonal antibodies, ADCs, bispecific antibodies and recombinant proteins. Due to his close relationship to the Technical University of Darmstadt where he teaches and supervises master- and PhD students, Björn has a deep understanding of scientific trends in protein engineering.


Björn Hock PhD, Founder and CEO of Lavaux Biotech Consulting graduated from the University of Frankfurt am Main in Biochemistry. He worked for Merck KGaA for almost 20 years in various positions including «Global Head, Protein Engineering and Antibody Technologies» and «Global Head, ADC and Targeted Therapeutics». In 2017, Björn moved to Switzerland to lead the Biologics Technology and Development Organization at Ferring Pharmaceuticals. In September 2021, he became the interim CEO and Head of European division at Aerium Therapeutics (formerly SwissThera SA) where he built the European office and drove CMC- and preclinical development of lead assets (anti-SARS-Cov-2 antibodies) with unprecedented timelines (gene to first in human in less than 8 months).

Björn has a close relationship to academia and is habilitated at the Technical University of Darmstadt.